谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

A First-in-human, Open-Label, Dose-Escalation and Dose-Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics/pharmacodynamics, and Antitumor Activity of QL1604, a Humanized Anti–pd-1 Mab, in Patients with Advanced or Metastatic Solid Tumors

Zhiyu Huang,Yanjun Xu,Wei Hong,Lei Gong,Kaiyan Chen,Jing Qin,Fajun Xie,Feng Wang,Xin Tian,Xiangrui Meng, Wenlei Feng,Lingyan Li,Baihui Zhang,Xiaoyan Kang,Yun Fan

Frontiers in Immunology（2023）

引用 0|浏览15
关键词
QL1604,anti-PD-1 mAb,advanced solid tumors,tolerability,first-in-human
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要